KMTS Stock Analysis: Kestra Medical | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.603m USD | 12M Return: 24.8% | BMG524411052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.91M
Qual. Beats: 0
Rev. Trend: 99.0%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 1.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS) is a wearable medical device and digital healthcare company focused on improving outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company was founded in 2014 and is headquartered in Kirkland, Washington.
The company develops and commercializes the Cardiac Recovery System platform, an integrated ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable recovery periods. Core components include the ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors heart rhythms and automatically delivers defibrillation therapy upon detecting life-threatening ventricular arrhythmias, along with digital patient engagement tools and clinical workflow solutions aimed at improving adherence, enabling care coordination, and generating actionable clinical insights.
Kestra operates within the Health Care Equipment sub-industry, a segment of the broader medical devices sector that includes manufacturers of diagnostic, therapeutic, and patient monitoring equipment. Wearable cardioverter defibrillators represent a specialized niche focused on temporary cardiac protection for patients who are not immediate candidates for implantable devices.
- ASSURE WCD market share gains against ZOLL LifeVest
- CMS reimbursement decisions impact WCD revenue outlook
- IPO cash burn management and path to profitability
| Net Income: -149.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA 1.25 > 1.0 |
| NWC/Revenue: 166.8% < 20% (prev 283.8%; Δ -117.0% < -1%) |
| CFO/TA -0.25 > 3% & CFO -87.7m > Net Income -149.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.6m) vs 12m ago 14.15% < -2% |
| Gross Margin: 53.89% > 18% (prev 43.46%; Δ 10.42% > 0.5%) |
| Asset Turnover: 34.78% > 50% (prev 24.94%; Δ 9.85% > 0%) |
| Interest Coverage Ratio: -18.52 > 6 (EBIT TTM -140.1m / Interest Expense TTM 7.56m) |
| A: 0.51 (Total Current Assets 226.3m - Total Current Liabilities 48.3m) / Total Assets 347.4m |
| B: -2.00 (Retained Earnings -695.9m / Total Assets 347.4m) |
| C: -0.46 (EBIT TTM -140.1m / Avg Total Assets 306.8m) |
| D: 1.78 (Book Value of Equity 222.4m / Total Liabilities 125.0m) |
| Altman-Z'' = -4.37 = D |
| DSRI: 1.04 (Receivables 15.4m/9.25m, Revenue 106.7m/66.4m) |
| GMI: 0.81 (GM 43.46% / 53.89%) |
| AQI: 13.05 (AQ_t 0.16 / AQ_t-1 0.01) |
| SGI: 1.61 (Revenue 106.7m / 66.4m) |
| TATA: -0.18 (NI -149.9m - CFO -87.7m) / TA 347.4m) |
| Beneish M = 4.39 (Cap -4..+1) = D |
As of October 16, 2026, the stock is trading at USD 28.68 with a total of 405,357 shares traded. Over the past week, the price has changed by +11.29%, over one month by +13.90%, over three months by +16.51% and over the past year by +24.75%.
Current recommended Stop Loss: 26.60 (which is 7.3% or 1.5 ATR below the current price).
Kestra Medical has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy KMTS.
- StrongBuy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 30.3 | 5.6% |
P/S = 15.018
P/B = 6.8333
Revenue TTM = 106.7m USD
EBIT TTM = -140.1m USD
EBITDA TTM = -130.7m USD
Long Term Debt = 72.5m USD (from longTermDebt, last quarter)
Short Term Debt = 23.0k USD (from shortTermDebt, last quarter)
Debt = 80.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 3.95m
Net Debt = -118.5m USD (calculated: Debt 80.4m - CCE 198.9m)
Enterprise Value = 1.48b USD (1.60b + Debt 80.4m - CCE 198.9m)
Interest Coverage Ratio = -18.52 (Ebit TTM -140.1m / Interest Expense TTM 7.56m)
EV/FCF = -10.83x (Enterprise Value 1.48b / FCF TTM -137.0m)
FCF Yield = -9.23% (FCF TTM -137.0m / Enterprise Value 1.48b)
FCF Margin = -128.4% (FCF TTM -137.0m / Revenue TTM 106.7m)
Net Margin = -140.4% (Net Income TTM -149.9m / Revenue TTM 106.7m)
Gross Margin = 53.89% ((Revenue TTM 106.7m - Cost of Revenue TTM 49.2m) / Revenue TTM)
Gross Margin QoQ = 56.50% (prev 54.76%)
Tobins Q-Ratio = 4.27 (Enterprise Value 1.48b / Total Assets 347.4m)
Interest Expense / Debt = 9.41% (Interest Expense 7.56m / Debt 80.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -110.7m (EBIT -140.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.05 (Total Current Assets 226.3m / Total Current Liabilities 74.2m)
Debt / Equity = 0.36 (Debt 80.4m / totalStockholderEquity, last quarter 222.4m)
Debt / EBITDA = 0.91 (negative EBITDA) (Net Debt -118.5m / EBITDA -130.7m)
Debt / FCF = 0.87 (negative FCF - burning cash) (Net Debt -118.5m / FCF TTM -137.0m)
Total Stockholder Equity = 233.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -48.85% (Net Income -149.9m / Total Assets 347.4m)
RoE = -64.18% (Net Income TTM -149.9m / Total Stockholder Equity 233.5m)
RoCE = -45.78% (EBIT -140.1m / Capital Employed (Equity 233.5m + L.T.Debt 72.5m))
RoIC = -37.67% (negative operating profit) (NOPAT -110.7m / Invested Capital 293.8m)
WACC = 9.52% (E(1.60b)/V(1.68b) * Re(9.63%) + D(80.4m)/V(1.68b) * Rd(9.41%) * (1-Tc(0.21)))
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.44 | Cagr: 7.73%
[DCF] Fair Price = unknown (Cash Flow -137.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.36 | # QB: 0
Revenue Correlation: 99.01 | Revenue CAGR: 84.94% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-10-31): EPS=-0.60 | Chg30d=+1.63% | Revisions=+40% | Analysts=2
EPS next Quarter (2027-01-31): EPS=-0.57 | Chg30d=-1.77% | Revisions=-25% | Analysts=2
EPS current Year (2027-04-30): EPS=-2.45 | Chg30d=-6.29% | Revisions=-40% | GrowthEPS=-43.4% | GrowthRev=+48.1%
EPS next Year (2028-04-30): EPS=-2.06 | Chg30d=-1.73% | Revisions=-25% | GrowthEPS=+16.1% | GrowthRev=+39.0%
[Analyst] Revisions Ratio: -22% (up=2, down=4)